5

15

20

## CLAIMS

- 1. Use of a compound capable of modulating the activity of calpain for the preparation of a pharmaceutical composition for the treatment of cancer.
- 2. Use according to claim 1, characterized in that the compound is a protein or a polypeptide which is an inhibitor of the activity of calpain, or a nucleic acid sequence encoding such a polypeptide or protein.
- in that the compound is a protein or a polypeptide which is a specific inhibitor of the activity of calpain on the wild-type p53 protein, or a nucleic acid sequence encoding such a polypeptide or protein.
  - 4. Use according to claim 2 or 3, characterized in that the nucleic acid is part of a vector.
    - 5. Use according to claim 4, characterized in that the nucleic acid is part of a viral vector, chosen from adenoviruses, retroviruses and adeno-associated viruses.
    - 6. Use according to claim 4, characterized in that the nucleic acid is part of a lipid liposomal vector.
- 7. Use according to one of the preceding claims, characterized in that the compound is a nucleic acid encoding all or part of calpastatin.

10

15

25

- 8. Use according to claim 7, characterized in that the nucleic acid comprises all or part of the sequence SEQ ID No. 1 or a derivative thereof.
- 9. Use according to claim 8, characterized in that the nucleic acid is chosen from the sequences SEQ ID No. 1 and 2.
  - 10. Use according to claim 8, characterized in that the nucleic acid is chosen from the derivatives of the sequences SEQ ID No. 1 or 2 encoding specific inhibitors of the degradation of the wild-type p53 protein.
  - 11. Use according to one of claims 1 to 6, characterized in that the compound is a derivative of calpain capable of specifically degrading the mutated p53 proteins.
  - 12. Viral vector comprising a nucleic acid sequence encoding a protein or a polypeptide which is an inhibitor of the activity of calpain.
- 13. Vector according to claim 12,
  20 characterized in that it is chosen from the
  adenoviruses, retroviruses and adeno-associated
  viruses.
  - or 13, characterized in that it comprises a sequence encoding all or part of calpastatin.
    - 15. Vector according to claim 12, characterized in that it comprises a sequence encoding a derivative of calpain capable of specifically

degrading the mutated p53 proteins.

16. Pharmaceutical composition comprising a nucleic acid sequence encoding all or part of calpastatin or a derivative of calpain capable of specifically degrading the mutated p53 proteins.

17. Composition according to claim 16, formulated for inttra-tymour administration.

100 120

5

add Bi